Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory tests and pathological activation. A platform can assist in matching teams of nationally and internationally authoritative experts to provide accurate diagnosis and treatment programs.
Treatment and management of primary carcinoma deficiency syndrome requires individual development of treatment programs, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multidimensional management. In recent years, with the development of therapeutic, immunoregulatory and precision medicine, many previously difficult-to-treat genetic metabolic disorders have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustments according to the changes in disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of primary carcinoma deficiency syndrome. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.